[HTML][HTML] FUT11 as a potential biomarker of clear cell renal cell carcinoma progression based on meta-analysis of gene expression data
E Zodro, M Jaroszewski, A Ida, T Wrzesiński, Z Kwias… - Tumor Biology, 2014 - Springer
In this paper, we provide a comprehensive summary of available clear cell renal cell
carcinoma (ccRCC) microarray data in the form of meta-analysis of genes differentially …
carcinoma (ccRCC) microarray data in the form of meta-analysis of genes differentially …
Curcumin analogue A501 induces G2/M arrest and apoptosis in non-small cell lung cancer cells
YQ Xia, XY Wei, WL Li, K Kanchana… - Asian Pacific Journal …, 2014 - koreascience.kr
Curcumin and its analogues have been reported to exert anti-cancer activity against a
variety of tumors. Here, we reported A501, a new curcumin analogue. The effect of A501 on …
variety of tumors. Here, we reported A501, a new curcumin analogue. The effect of A501 on …
Single nucleotide polymorphisms as susceptibility, prognostic, and therapeutic markers of nonsmall cell lung cancer
S Zienolddiny, V Skaug - Lung Cancer: Targets and Therapy, 2011 - Taylor & Francis
Lung cancer is a major public health problem throughout the world. Among the most
frequent cancer types (prostate, breast, colorectal, stomach, lung), lung cancer is the leading …
frequent cancer types (prostate, breast, colorectal, stomach, lung), lung cancer is the leading …
Pitfalls in lung cancer molecular pathology: how to limit them in routine practice?
M Ilie, P Hofman - Current medicinal chemistry, 2012 - ingentaconnect.com
New treatment options in advanced non-small cell lung carcinoma (NSCLC) targeting
activating epidermal growth factor receptor (EGFR) gene mutations and other genetic …
activating epidermal growth factor receptor (EGFR) gene mutations and other genetic …
Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC)(stage IIIB/IV) followed by platinum-based …
F Zappa, C Droege, D Betticher, R von Moos… - Lung cancer, 2012 - Elsevier
PURPOSE: This phase II trial aimed to evaluate feasibility and efficacy of a first-line
combination of targeted therapies for advanced non-squamous NSCLC: bevacizumab (B) …
combination of targeted therapies for advanced non-squamous NSCLC: bevacizumab (B) …
[HTML][HTML] The study on newly developed McAb NJ001 specific to non-small cell lung cancer and its biological characteristics
S Pan, F Wang, P Huang, T Xu, L Zhang, J Xu, Q Li… - PloS one, 2012 - journals.plos.org
Monoclonal antibody (McAb) is the key tool for cancer immunodiagnosis and
immunotherapy. McAb-based immunotherapy that targets tumor antigens has had great …
immunotherapy. McAb-based immunotherapy that targets tumor antigens has had great …
[HTML][HTML] High expression of LAMP1 as a prognostic marker in patients with epithelial ovarian cancer
Y Xu, X Cao, S Zhang, Y Zhang… - International Journal of …, 2017 - ncbi.nlm.nih.gov
Abstract Lysosome Associated Membrane Protein-1 (LAMP1), expressed in several
functional processes, is a heavily glycosylated lysosomal membrane protein which is able to …
functional processes, is a heavily glycosylated lysosomal membrane protein which is able to …
[HTML][HTML] Six-Gene Signature for Differential Diagnosis and Therapeutic Decisions in Non-Small-Cell Lung Cancer—A Validation Study
R Charkiewicz, A Sulewska, P Karabowicz… - International Journal of …, 2024 - mdpi.com
Non-small-cell lung cancer (NSCLC) poses a challenge due to its heterogeneity,
necessitating precise histopathological subtyping and prognostication for optimal treatment …
necessitating precise histopathological subtyping and prognostication for optimal treatment …
Human positive coactivator 4 is a potential novel therapeutic target in non-small cell lung cancer
Abstract Transcriptional positive coactivator 4 (PC4) is a multifunctional nuclear protein that
has important roles in DNA transcription, replication, repair and heterochromatinization …
has important roles in DNA transcription, replication, repair and heterochromatinization …
[HTML][HTML] Molecular predictors of response to tyrosine kinase inhibitors in patients with non-small-cell lung cancer
Introduction Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have
become a treatment option in non-small-cell lung cancer (NSCLC) patients. However …
become a treatment option in non-small-cell lung cancer (NSCLC) patients. However …